BCIQ Profiles

Company Profile ReportTarget Profile Report
0713 ECP Prime Medicine EMBARGO Tues 6AM ET
BioCentury & Getty Images

Emerging Company Profile

Prime Medicine: adding versatility to gene editing

Emerging Company Profile: David Liu’s latest gene editing play is developing a next-generation platform to rewrite DNA

Co-founded by David Liu, Prime Medicine is developing a next-generation gene editing technology that makes more types of genetic alterations without the off-target concerns.

Jul 13, 2021 | 11:03 AM GMT

CRISPR-Cas9 gene editing has only started to scratch the surface of its clinical potential, but next-generation iterations including prime editing from new company Prime aren’t far behind.

Prime Medicine Inc. launched on Tuesday with $315 million in funding and a CRISPR-based technology that adds flexibility

Read the full 1107 word article

How to gain access

Continue reading with a
two-week free trial.